January 9, 2018 / 7:20 AM / 7 months ago

BRIEF-Bergenbio Meets First Efficacy Endpoint In Phase II Trial

Jan 9 (Reuters) - Bergenbio Asa:

* BERGENBIO MEETS FIRST EFFICACY ENDPOINT IN PHASE II TRIAL WITH SELECTIVE AXL INHIBITOR BGB324 (BEMCENTINIB) IN NSCLC

* ‍EXPECTS TO PRESENT CLINICAL DATA FROM THIS STUDY AT AN INTERNATIONAL CANCER CONFERENCE DURING 2018​ Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below